Loading
Loading
Product image is a representation — actual packaging and label may vary.
Nasal Sprays · 7ml
🕐 Pre-order — ships from 31 August 2026
This product is pre-order only right now. Your order will be dispatched once stock arrives on 31 August 2026.
$119
AUD · 1 pack
Flat rate · ships with your order
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist derived from alpha-MSH, studied in preclinical and clinical research for its role in sexual function. Research has examined its potential to act on central MC3R/MC4R pathways, improve erectile function through corpus cavernosum smooth muscle relaxation, and enhance sexual desire via CNS-mediated libido regulation. Its mechanism is distinct from PDE5-inhibitor pathways, with rapid onset demonstrated in evaluations.
Chemical Properties
Research Use Only — Disclaimer
These consumable supplies are intended solely for use in research and laboratory settings. All items are sterile and individually packaged for professional handling. BAC water is for peptide reconstitution purposes only and is not intended for injection without appropriate professional supervision. Not for human or animal consumption in any form.
PT-141
Bremelanotide
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide related to Melanotan II, differing at the C-terminus. It was identified serendipitously during MT-2 human trials when researchers noted sexual arousal as a prominent effect. Approved by the FDA in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Unlike PDE5 inhibitors (sildenafil, tadalafil) which act peripherally through vascular smooth muscle relaxation, PT-141 acts centrally via melanocortin MC4R in the hypothalamus and limbic system, activating dopaminergic pathways associated with sexual motivation, desire, and arousal. This central mechanism means it can activate sexual response in the absence of physical stimulation and works through the same neural pathway in both men and women.
Clinical trials demonstrated improvement in sexually satisfying events and desire scores in premenopausal women with HSDD. Studies in male sexual dysfunction showed dose-dependent improvement in erectile response. Unlike MT-2, PT-141's reduced MC1R activity means it produces minimal melanogenesis at therapeutic doses. Key side effects in trials included transient nausea, flushing, and blood pressure elevation.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
